{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:25Z","timestamp":1786997905717,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007956","name":"Nanjing University of Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.virol.2026.110799","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:55:22Z","timestamp":1769010922000},"page":"110799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Favipiravir's clinical potential for treating Severe Fever with Thrombocytopenia Syndrome (SFTS): A narrative review"],"prefix":"10.1016","volume":"617","author":[{"given":"Xinhan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7925-0945","authenticated-orcid":false,"given":"Huaying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.virol.2026.110799_bib1","article-title":"Enrichment strategies for clinical trials targeting skin fibrosis and interstitial lung disease in systemic sclerosis","volume":"35","author":"Ariane","year":"2023","journal-title":"Curr. Opin. Rheumatol."},{"issue":"3","key":"10.1016\/j.virol.2026.110799_bib2","article-title":"Modeling severe fever with thrombocytopenia syndrome virus infection in golden Syrian hamsters: importance of STAT2 in preventing disease and effective treatment with favipiravir","volume":"91","author":"Brian","year":"2016","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.virol.2026.110799_bib3","article-title":"Recent research advances in the development of dabie Banda virus vaccines","volume":"18","author":"Chenyang","year":"2024","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"0","key":"10.1016\/j.virol.2026.110799_bib4","article-title":"Favipiravir (T-705) protects against peracute rift valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment","volume":"104","author":"Dionna","year":"2014","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.virol.2026.110799_bib5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/cid\/cir776","article-title":"Person-to-person transmission of severe fever with thrombocytopenia syndrome bunyavirus through blood contact","volume":"54","author":"Gai","year":"2012","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.virol.2026.110799_bib6","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1128\/CVI.00222-13","article-title":"Human antibody neutralizes severe fever with thrombocytopenia syndrome virus, an emerging hemorrhagic fever virus","volume":"20","author":"Guo","year":"2013","journal-title":"Clin. Vaccine Immunol. : CVI"},{"issue":"11","key":"10.1016\/j.virol.2026.110799_bib7","article-title":"Characterization of glycoprotein-mediated entry of severe fever with thrombocytopenia syndrome virus","volume":"90","author":"Hideki","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2026.110799_bib8","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jhin.2021.10.023","article-title":"Predisposing factors for person-to-person transmission of severe fever with thrombocytopenia syndrome bunyavirus","volume":"123","author":"Hu","year":"2022","journal-title":"J. Hosp. Infect."},{"issue":"11","key":"10.1016\/j.virol.2026.110799_bib9","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.3201\/eid2211.160414","article-title":"Neutralizing antibodies to severe fever with thrombocytopenia syndrome virus 4 years after hospitalization, China","volume":"22","author":"Huang","year":"2016","journal-title":"Emerg. Infect. Dis."},{"issue":"0","key":"10.1016\/j.virol.2026.110799_bib10","article-title":"Cyclophilin A causes severe fever with thrombocytopenia syndrome virus-induced cytokine storm by regulating mitogen-activated protein kinase pathway","volume":"13","author":"Huaying","year":"2022","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.virol.2026.110799_bib11","article-title":"Epidemiology, clinical characteristics, and treatment of severe fever with thrombocytopenia syndrome","volume":"1","author":"Jia-Chen","year":"2022","journal-title":"Infect. Med."},{"issue":"11","key":"10.1016\/j.virol.2026.110799_bib12","article-title":"Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: korean experiences and perspectives","volume":"13","author":"Joon Young","year":"2015","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"5","key":"10.1016\/j.virol.2026.110799_bib13","doi-asserted-by":"crossref","first-page":"633.e631","DOI":"10.1016\/j.cmi.2019.01.006","article-title":"Nosocomial person-to-person transmission of severe fever with thrombocytopenia syndrome","volume":"25","author":"Jung","year":"2019","journal-title":"Clin. Microbiol. Infection : Off. Publ. Europ. Soc. Clin. Microbiol. Infect. Dis."},{"issue":"7","key":"10.1016\/j.virol.2026.110799_bib14","article-title":"Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP","volume":"118","author":"Katerina","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"0","key":"10.1016\/j.virol.2026.110799_bib15","article-title":"Antiviral therapy for COVID-19: derivation of optimal strategy based on past antiviral and favipiravir experiences","volume":"235","author":"Kimiyasu","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"0","key":"10.1016\/j.virol.2026.110799_bib16","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Kimiyasu","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.virol.2026.110799_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-021-00541-3","article-title":"Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndrome","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"8","key":"10.1016\/j.virol.2026.110799_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110039","article-title":"Single-cell landscape of peripheral immune responses to fatal SFTS","volume":"37","author":"Li","year":"2021","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.virol.2026.110799_bib19","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1473-3099(18)30293-7","article-title":"Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia syndrome in China, 2011-17: a prospective observational study","volume":"18","author":"Li","year":"2018","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.virol.2026.110799_bib20","article-title":"Nucleobases and corresponding nucleosides display potent antiviral activities against dengue virus possibly through viral lethal mutagenesis","volume":"12","author":"Li","year":"2018","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"5","key":"10.1016\/j.virol.2026.110799_bib21","article-title":"Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever","volume":"8","author":"Lisa","year":"2014","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"2","key":"10.1016\/j.virol.2026.110799_bib22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/rmv.1776","article-title":"Systematic review of severe fever with thrombocytopenia syndrome: virology, epidemiology, and clinical characteristics","volume":"24","author":"Liu","year":"2014","journal-title":"Rev. Med. Virol."},{"issue":"2","key":"10.1016\/j.virol.2026.110799_bib23","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1089\/vbz.2011.0758","article-title":"Person-to-person transmission of severe fever with thrombocytopenia syndrome virus","volume":"12","author":"Liu","year":"2012","journal-title":"Vector Borne Zoonotic Dis."},{"issue":"15","key":"10.1016\/j.virol.2026.110799_bib24","article-title":"Rational design and bioactive screening of peptide inhibitors targeting host-pathogen interactions in severe fever with Thrombocytopenia syndrome virus","volume":"26","author":"Lixin","year":"2025","journal-title":"Chembiochem"},{"issue":"6","key":"10.1016\/j.virol.2026.110799_bib25","article-title":"Effects of ribavirin on severe fever with thrombocytopenia syndrome virus in vitro","volume":"67","author":"Masayuki","year":"2014","journal-title":"Jpn. J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.virol.2026.110799_bib26","article-title":"Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized phase III trial","volume":"69","author":"Matthew","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"issue":"0","key":"10.1016\/j.virol.2026.110799_bib27","article-title":"Risk factors of severe fever with thrombocytopenia syndrome combined with central neurological complications: a five-year retrospective case-control study","volume":"13","author":"Min","year":"2022","journal-title":"Front. Microbiol."},{"issue":"0","key":"10.1016\/j.virol.2026.110799_bib28","article-title":"The endless wars: severe fever with thrombocytopenia syndrome virus, host immune and genetic factors","volume":"12","author":"Min","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"1","key":"10.1016\/j.virol.2026.110799_bib29","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12889-025-21527-8","article-title":"Relationship between meteorological factors and the incidence of severe fever with thrombocytopenia syndrome: a systematic review and meta-analysis","volume":"25","author":"Mo","year":"2025","journal-title":"BMC Public Health"},{"issue":"8","key":"10.1016\/j.virol.2026.110799_bib30","article-title":"Ribavirin--current status of a broad spectrum antiviral agent","volume":"2","author":"N J","year":"2001","journal-title":"Expet Opin. Pharmacother."},{"issue":"7","key":"10.1016\/j.virol.2026.110799_bib31","first-page":"918","article-title":"Diagnosis and treatment scheme for severe fever with thrombocytopenia syndrome(2023 Edition)","volume":"23","year":"2024","journal-title":"Chin. J. Infect. Control"},{"issue":"6","key":"10.1016\/j.virol.2026.110799_bib32","article-title":"Insights on multi-spectroscopic approaches for estimating the in vitro binding of favipiravir with adenine nucleotide","volume":"39","author":"Reem N","year":"2024","journal-title":"Luminescence"},{"issue":"1","key":"10.1016\/j.virol.2026.110799_bib33","article-title":"Ruxolitinib plus standard of care in severe hospitalized adults with severe fever with thrombocytopenia syndrome (SFTS): an exploratory, single-arm trial","volume":"22","author":"Sai","year":"2024","journal-title":"BMC Med."},{"issue":"2","key":"10.1016\/j.virol.2026.110799_bib34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s15010-019-01364-9","article-title":"Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705)","volume":"48","author":"Song","year":"2020","journal-title":"Infection"},{"issue":"2","key":"10.1016\/j.virol.2026.110799_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009103","article-title":"A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome","volume":"15","author":"Suemori","year":"2021","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"1","key":"10.1016\/j.virol.2026.110799_bib36","first-page":"9236","article-title":"The changing epidemiological characteristics of severe fever with thrombocytopenia syndrome in China, 2011\u20132016","volume":"7","author":"Sun","year":"2017","journal-title":"Rep"},{"issue":"1","key":"10.1016\/j.virol.2026.110799_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00061-15","article-title":"Efficacy of T-705 (Favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus","volume":"1","author":"Tani","year":"2016","journal-title":"mSphere"},{"issue":"10","key":"10.1016\/j.virol.2026.110799_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206416","article-title":"Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: Dose-efficacy studies upon oral administration","volume":"13","author":"Tani","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.virol.2026.110799_bib39","article-title":"Overview of the immunological mechanism underlying severe fever with thrombocytopenia syndrome","volume":"50","author":"Tao","year":"2022","journal-title":"Int. J. Mol. Med."},{"issue":"10","key":"10.1016\/j.virol.2026.110799_bib40","article-title":"Adaptive platform trials: definition, design, conduct and reporting considerations","volume":"18","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.virol.2026.110799_bib42","article-title":"Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials","volume":"9","author":"Vincent","year":"2020","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"1","key":"10.1016\/j.virol.2026.110799_bib44","article-title":"A broadly protective antibody targeting glycoprotein Gn inhibits severe fever with thrombocytopenia syndrome virus infection","volume":"15","author":"Xuanxiu","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.virol.2026.110799_bib45","article-title":"Nonmuscle myosin heavy chain IIA is a critical factor contributing to the efficiency of early infection of severe fever with thrombocytopenia syndrome virus","volume":"88","author":"Yinyan","year":"2013","journal-title":"J. Virol."},{"issue":"0","key":"10.1016\/j.virol.2026.110799_bib46","article-title":"Limitations of a proper SFTSV mouse model using human C-type lectin receptors","volume":"15","author":"You-Min","year":"2025","journal-title":"Front. Microbiol."},{"issue":"2","key":"10.1016\/j.virol.2026.110799_bib47","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Yousuke","year":"2013","journal-title":"Antivir. Res."},{"issue":"16","key":"10.1016\/j.virol.2026.110799_bib48","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1056\/NEJMoa1010095","article-title":"Fever with thrombocytopenia associated with a novel bunyavirus in China","volume":"364","author":"Yu","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"0","key":"10.1016\/j.virol.2026.110799_bib49","article-title":"The mechanism of action of T-705 as a unique delayed chain terminator on influenza viral polymerase transcription","volume":"277","author":"Yuqing","year":"2021","journal-title":"Biophys. Chem."},{"issue":"1","key":"10.1016\/j.virol.2026.110799_bib50","article-title":"Efficacy and safety of directly acting antiviral drugs in HCV patients with HIV in liver transplantation: a meta-analysis","volume":"1","author":"Zeng","year":"2023","journal-title":"Decod. Infect. Trans."},{"issue":"1","key":"10.1016\/j.virol.2026.110799_bib51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12250-016-3931-1","article-title":"Current status of severe fever with thrombocytopenia syndrome in China","volume":"32","author":"Zhan","year":"2017","journal-title":"Virol. Sin."},{"issue":"31","key":"10.1016\/j.virol.2026.110799_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg6856","article-title":"CCR2 is a host entry receptor for severe fever with thrombocytopenia syndrome virus","volume":"9","author":"Zhang","year":"2023","journal-title":"Sci. Adv."},{"issue":"8","key":"10.1016\/j.virol.2026.110799_bib53","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1016\/S2542-5196(20)30145-5","article-title":"Distribution of Haemaphysalis longicornis and associated pathogens: analysis of pooled data from a China field survey and global published data","volume":"4","author":"Zhao","year":"2020","journal-title":"Lancet Planet. Health"},{"issue":"1","key":"10.1016\/j.virol.2026.110799_bib54","article-title":"Analysis of the clinical efficacy of CCBs in patients with severe fever with thrombocytopenia syndrome combined with hypertension","volume":"22","author":"Ziruo","year":"2025","journal-title":"Virol. J."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682226000140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682226000140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T07:48:38Z","timestamp":1773992918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682226000140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":52,"alternative-id":["S0042682226000140"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2026.110799","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Favipiravir's clinical potential for treating Severe Fever with Thrombocytopenia Syndrome (SFTS): A narrative review","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2026.110799","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110799"}}